Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Minerva Surgical, Inc. - Common Stock
(NQ:
UTRS
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Dec 28, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Minerva Surgical, Inc. - Common Stock
Earnings Scheduled For March 8, 2022
↗
March 08, 2022
Companies Reporting Before The Bell • Babcock & Wilcox (NYSE:BW) is likely to report quarterly earnings at $0.10 per share on revenue of $196.62 million. •...
Via
Benzinga
Minerva Surgical's Preliminary FY21 Revenues Top Expectations
↗
January 12, 2022
Medical device company Minerva Surgical Inc (NASDAQ: UTRS) expects Q4 FY21 sales of $13.5 million - $13.7 million, versus $13.6 million posted a year ago and the...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 16, 2021
↗
November 16, 2021
Upgrades According to Maxim Group, the prior rating for VirTra Inc (NASDAQ:
Via
Benzinga
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
↗
November 14, 2021
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at...
Via
Benzinga
4 Stocks Insiders Are Buying
↗
October 29, 2021
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go...
Via
Benzinga
The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs
↗
October 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Athira Names Chief Operating Officer Mark Litton As Next CEO as Leen Kawas...
Via
Benzinga
55 Biggest Movers From Friday
↗
October 25, 2021
Gainers Phunware, Inc. (NASDAQ: PHUN) shares jumped 471.2% to close at $8.74 on Friday. Phunware shares jumped over 45% on Thursday, possibly in sympathy with Digital World...
Via
Benzinga
The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs
↗
October 18, 2021
Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news....
Via
Benzinga
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
↗
October 24, 2021
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...
Via
Benzinga
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today